fbpx

Dr Peter Fakler (Phd)

MSc PhD
Scientific consultant

Since 2015 Dr Fakler has been a scientific Consultant at NIIM for various academic roles including literature research, laboratory research, data processing and assisting with course development.

Dr Fakler has a Master of Science degree (major in biology, minors in chemistry and mathematics) and a PhD from the University of Heidelberg, Germany, where he investigated molecular genetic and biochemical variations in mammals.

Since moving to Australia in 1999, his interests have ranged from exploring and documenting Australia’s natural history to understanding the causes of chronic diseases and ageing.

Peter has been particularly interested in the roles of vitamins and other nutrients in health, especially their biochemical functions. Peter has co-authored a number of peer-reviewed journal articles including on effects of cocoa, tomato-extract, and garlic on cardiovascular health, and has contributed to NIIM’s Short Course in Integrative Medicine.

 Dr Fakler has contributed to innovative and cutting-edge techniques in the NIIM laboratory, including

  • Circulating Tumour Cell (CTC) Analysis (http://niim.com.au/ctc)
  • NIIM’s Pathogen Test combining CTC testing by microscopy, DNA extraction and PCR analysis of pathogens found in blood (http://niim.com.au/pathogen)
  • Dr Peter Fakler is co-inventor on the Innovation Patent filed in 2017

 Ried K, Fakler P. Innovation Patent AU 2017101397 A4: Identifying Biological Agents Present In Animal Bodily Fluid
http://pericles.ipaustralia.gov.au/ols/auspat/applicationDetails.do?applicationNo=2017101397

The patented methodology lead to the discovery and publication of

Ried K, Fakler P. Rare fungal infection linked to a case of juvenile arthritis. Cureus 2018, 10 (3): e3229

Since 2022, Dr Fakler has been involved in the innovative viral reactivation testing via Immuno-Cyto-Chemistry (ICC) combining the Circulating Rare Cells Test (http://niim.com.au/ctc) and ICC (viral anti-body testing on human cells in the blood) as part of the Alliance Long COVID Trial (http://niim.com.au/longcovid), the only study of its kind in Australia in 2023.